EMPACT-Us: Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients

Sponsor
Family Health Centers of San Diego (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05750537
Collaborator
University of California, San Diego (Other), Tobacco Related Disease Research Program (Other)
13,496
2
2
27.5
6748
245.1

Study Details

Study Description

Brief Summary

This research study is being conducted to test the effectiveness of the Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use (EMPACT-Us), an innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.

We hypothesize that EMPACT-Us will be more effective than the newly-enhanced usual care on improving engagement in tobacco treatments, quit attempts and biochemically verified cessation at 6-and 12-months post initial offerings.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: EMPACT-Us
N/A

Detailed Description

The investigators propose a stepped-wedge cluster randomized trial. Eight of the largest FHCSD clinics with geographic distribution covering a wide region of San Diego were selected. Based on chart review, the investigators estimate that there are 13,496 tobacco users who are active patients at the selected clinics and could present to one or more clinics during the study period. This population represents roughly 70% of the tobacco users at FHCSD. The larger clinics are chosen based on size, special populations represented, and staff size. The study duration was divided into five 6-month periods. After a baseline period, four pairs of clinics (8 total clinics) will be assigned randomly to begin the active treatment at one of the four subsequent periods. No other clinic characteristics are used for randomization. Tobacco users first tobacco-related visit will anchor subsequent assessments of tobacco use and engagement in tobacco treatments within their electronic medical records and in surveys during the duration of the study.

Activities are designed to evaluate tobacco treatments within FHCSD and to generalize these evaluations to other health clinics serving similar low-income communities. Activities are organized within the Milestones, each building upon the other, leading to the ultimate test of two workflows offering a suite of tobacco cessation services. Milestone 1 (1-6mo) includes startup and training (TE Coach curriculum adaptation, MA training, Primary Care Provider (PCP) training) and baseline data collection using system-level infrastructure assessment and rapid, iterative improvement; Milestone 2 (6-33mo) includes the testing of EMPACT-Us suite of services, with evaluation and fidelity checks built into implementation through Milestone 3 (4-33mo.), which will include conducting qualitative semi-structured interviews and surveys designed to understand the experiences of patients, N-MAs, PCPs, and TE Coaches. Staff will be interviewed either in person or remotely, while patients will be offered surveys either remotely over the phone or via email or SMS beginning two to four weeks after their index visit.; Milestone 4 (7-35mo) data analysis weaves through most of the study to inform work as the investigation progresses; and Milestone 5 (6-36mo) manuscript preparation and dissemination, is planned throughout the study period and beyond.

For the current project, UC San Diego investigators and staff are engaged with FHCSD in delivering the intervention that the investigators partnered to develop. While primarily housed at UC San Diego, this project will include regular onsite interactions with clinical records, individual interviews, interacting with FHCSD providers and viewing clinical information in both clinical intervention training and evaluation roles that again will include contact with patient PHI. The investigators will be removing PHI prior to final qualitative and quantitative analyses and reporting results using de-identified data.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
13496 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Stepped-wedge cluster randomized controlled trialStepped-wedge cluster randomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients
Anticipated Study Start Date :
Mar 15, 2023
Anticipated Primary Completion Date :
Jun 30, 2025
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: EMPACT-Us

An innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.

Behavioral: EMPACT-Us
A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.

No Intervention: Newly-enhanced usual care (EUC)

Newly-enhanced usual care (EUC)

Outcome Measures

Primary Outcome Measures

  1. Engagement with tobacco-use treatment as captured through Electronic Health Record queries [7 to 35 months]

    Engagement with tobacco use treatment is defined as at least one dose/session of evidence-based pharmacotherapy or behavioral counseling for smoking cessation using the EHR.

  2. Tobacco-use quit attempts as assessed through Electronic Health Record queries [7 to 35 months]

    Quit attempts are defined as the stated intention to achieve long-term cessation and an ability to refrain smoking evidenced by a self-reported 24-hour period of no smoking. ((e.g. C-TUQ: How long has it been since you last smoked a cigarette (even one or two puffs)?))

  3. Biochemically verified tobacco-use cessation as assessed through cotinine saliva test [6 and 12 months]

    Tobacco-use cessation is defined as prolonged abstinence at the 6- and 12- month follow periods, biochemically verified through cotinine saliva tests.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Current tobacco user

  • 18 years old

  • Speaks English or Spanish

No exclusions due to:
  • Nationality

  • Mental health status

  • Substance use

  • Race

  • Sexual orientation

  • Ethnicity

Inclusion into saliva collection:
  • Met level 1 criteria for inclusion into study

  • Reports abstinence at follow-up assessment

Exclusion Criteria:
  • Pregnant or breastfeeding women

  • Patients with a lung cancer diagnosis

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California San Diego San Diego California United States 92037
2 Family Health Centers of San Diego San Diego California United States 92102

Sponsors and Collaborators

  • Family Health Centers of San Diego
  • University of California, San Diego
  • Tobacco Related Disease Research Program

Investigators

  • Principal Investigator: David Strong, BA, MS, PhD, University of California, San Diego

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Family Health Centers of San Diego
ClinicalTrials.gov Identifier:
NCT05750537
Other Study ID Numbers:
  • T32CF4745
First Posted:
Mar 1, 2023
Last Update Posted:
Mar 1, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Family Health Centers of San Diego

Study Results

No Results Posted as of Mar 1, 2023